Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology*; D058846:Antibodies, Monoclonal, Murine-Derived; D000920:Antibody-Dependent Cell Cytotoxicity / Q000276:immunology; D018951:Antigens, CD20 / Q000096:biosynthesis / Q000097:blood / Q000276:immunology* / Q000378:metabolism*; D001402:B-Lymphocytes / Q000276:immunology / Q000378:metabolism; D001666:Binding Sites, Antibody; D045744:Cell Line, Tumor; D003179:Complement C3b / Q000378:metabolism; D003169:Complement Inactivator Proteins / Q000008:administration & dosage* / Q000494:pharmacology*; D003171:Complement Pathway, Classical / Q000276:immunology; D003165:Complement System Proteins / Q000096:biosynthesis / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy; D009895:Opsonin Proteins / Q000378:metabolism; D000069283:Rituximab; D044967:Serum / Q000502:physiology
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D003169:Complement Inactivator Proteins; D009895:Opsonin Proteins; D000069283:Rituximab; D003179:Complement C3b; D003165:Complement System Proteins